|
> I think you failed to see the "professor of public health policy" in his title. No, I did not. Public Health Policy and an MBA are non-clinical. Clinical Doctors that are actively treating Covid19 patients, that are actively using what will be Standard of Care using antivirals, anti-inflammatories, anticoagulants, steroids, ACE2 inhibitors, and other drugs, using well-known medical therapies for sick patients are the doctors that I want to hear from around treatment A, or treatment B. These are the doctors with the experience and the know-ho for these severe diseases. Again, as a radiologist, or hospital mgmt, the fine doctor is not a clinical doctor actively performing these treatments with these drugs and immunotherapies. Radiologists diagnose. This is the domain of an Infectious Diseases specialty in severe cases, and an Internist in less severe cases, with the active support of the associated other specialties (cardio/pulmonologists/vascular/etc for all the involved body parts for which there are specific specialties acutely impacted by covid). |
What does that have to do with reading and understanding studies? If you're treating patients, sure. But there are doctors that do research -- particularly those in pharma -- and in public policy.
I'm not sure why you want to continue to beat this dead dog of an argument.